secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2024-09-03T23:59:59+00:00
Accession:  0001645113-24-000029
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NovoCure CEO Asaf Danziger to retire Jan 1, 2025; CFO Ashley Cordova appointed CEO
--------------------------------------------------------------------------------

- CEO Asaf Danziger, in role since 2002, retires Jan 1, 2025; will remain on board and advise until early 2026.
- CFO Ashley Cordova named CEO effective Jan 1, 2025; she will stay as CFO until successor appointed.
- COO Wilco Groenhuysen resigns effective Oct 1, 2024; Mukund Paravasthu promoted to COO.
- Groenhuysen entered new employment agreement: base salary $615K/yr to Sept 2025 then $120K/yr to Apr 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511324000029/0001645113-24-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511324000029/nvcr-20240830.htm
  HTML page:      https://secwatch.observer/filing/0001645113-24-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer